Last reviewed · How we verify
Cinalong (CILNIDIPINE)
Cinalong (generic name: CILNIDIPINE) is a cilnidipine drug. It is currently in Phase 3 development.
Cilnidipine blocks calcium channels in blood vessels to lower blood pressure.
Cilnidipine is a small molecule that acts as a voltage-gated L-type calcium channel blocker. It has been studied in clinical trials for conditions such as hypertension, stroke, and metabolic syndrome X.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CILNIDIPINE |
|---|---|
| Drug class | cilnidipine |
| Target | Voltage-dependent N-type calcium channel subunit alpha-1B, Voltage-dependent T-type calcium channel subunit alpha-1H, Voltage-gated L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
Imagine your blood vessels are like roads with traffic lights. Calcium channels are like the traffic lights that control how much blood flows through the roads. Cilnidipine works by blocking these traffic lights, which helps to slow down the flow of blood and lower blood pressure.
Approved indications
Common side effects
- Renal impairment
- Hepatic function abnormal
- Cerebral infarction
- Interstitial lung disease
- Hyperkinetic heart syndrome
- Hyperkalaemia
- Cardiac failure
- Hyperuricaemia
- Embolic stroke
- Cerebral haemorrhage
- Platelet count decreased
- Cardiac vein perforation
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension (PHASE3)
- A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination With Coadministration of Cilnidipine and Valsartan (PHASE1)
- A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination Tablet With Coadministration of Cilnidipine and Valsartan (PHASE1)
- A Drug Interaction Study of Cilnidipine and Valsartan (PHASE1)
- Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD) (PHASE2)
- Cilnidipine Effect on High Blood Pressure and Cerebral Perfusion in Ischemic Stroke Patients With Hypertension (PHASE3)
- The Effects of Cilnidipine on Metabolic Syndrome Improvement (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cinalong CI brief — competitive landscape report
- Cinalong updates RSS · CI watch RSS
Frequently asked questions about Cinalong
What is Cinalong?
How does Cinalong work?
What is the generic name of Cinalong?
What drug class is Cinalong in?
What development phase is Cinalong in?
What are the side effects of Cinalong?
What does Cinalong target?
Related
- Drug class: All cilnidipine drugs
- Target: All drugs targeting Voltage-dependent N-type calcium channel subunit alpha-1B, Voltage-dependent T-type calcium channel subunit alpha-1H, Voltage-gated L-type calcium channel
- Therapeutic area: All drugs in Hematology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing